Home » ABT-199 Clinical Trials Suspended After Patient Death
ABT-199 Clinical Trials Suspended After Patient Death
Following a death due to tumor lysis syndrome, AbbVie has suspended the ABT-199 clinical trial program. ABT-199 is a promising new drug in development for chronic lymphocytic leukemia that was about to enter Phase III drug development by the company.
Biotech Strategy Blog
Biotech Strategy Blog
Upcoming Events
-
07May
-
14May
-
30May